GEN Exclusives

More »

GEN News Highlights

More »
Apr 30, 2009

Bayer and Regeneron Expand Development Program for VEGF Trap-Eye

  • Bayer HealthCare and Regeneron Pharmaceuticals are extending their global development program for Regeneron’s VEGF Trap-Eye to include central retinal vein occlusion (CRVO). The companies plan to initiate a Phase III study in the second half of this year.

    The program will consist of two, multinational, one-year clinical studies, which have been reviewed with regulatory authorities. The companies' partnership already includes two Phase III studies in patients with the wet age-related macular degeneration (AMD) and a Phase II trial in diabetic macular edema (DME). Enrollment in the wet AMD and DME studies is expected to be completed later this year.

    "Although CRVO is a leading cause of blindness, there is currently no treatment available that can be universally considered to be the standard of care, and there is no approved treatment to prevent the loss of vision or improve vision once it is lost," said Dr. Kemal Malik, head of global development and member of the Bayer HealthCare Executive Committee. "Since the underlying biology of CRVO is related to edema and the growth of abnormal new blood vessels that are mediated by vascular endothelial growth factor (VEGF), we are hopeful that VEGF Trap-Eye may help address this significant unmet medical need."

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »